Pfizer Inc. $PFE Shares Sold by Qsemble Capital Management LP

Qsemble Capital Management LP trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 41.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 122,644 shares of the biopharmaceutical company’s stock after selling 88,473 shares during the period. Qsemble Capital Management LP’s holdings in Pfizer were worth $2,953,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth $26,000. Keb Asset Management LLC acquired a new position in shares of Pfizer during the second quarter worth $26,000. HFM Investment Advisors LLC increased its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC lifted its holdings in Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PFE shares. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research note on Tuesday, June 9th. UBS Group restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Up 0.3%

Shares of NYSE:PFE opened at $26.88 on Tuesday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market cap of $153.21 billion, a P/E ratio of 35.37 and a beta of 0.34. The firm has a fifty day moving average price of $25.15 and a 200 day moving average price of $26.20.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business posted $0.78 earnings per share. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s dividend payout ratio is currently 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.